ATE448222T1 - 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe - Google Patents

2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Info

Publication number
ATE448222T1
ATE448222T1 AT04789522T AT04789522T ATE448222T1 AT E448222 T1 ATE448222 T1 AT E448222T1 AT 04789522 T AT04789522 T AT 04789522T AT 04789522 T AT04789522 T AT 04789522T AT E448222 T1 ATE448222 T1 AT E448222T1
Authority
AT
Austria
Prior art keywords
sub
sup
group
alkyl
member selected
Prior art date
Application number
AT04789522T
Other languages
English (en)
Inventor
Robert Scarborough
Wolin Huang
Anjali Pandey
Shawn Bauer
Xiaoming Zhang
Zhaozhong Jia
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Application granted granted Critical
Publication of ATE448222T1 publication Critical patent/ATE448222T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Alcoholic Beverages (AREA)
AT04789522T 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe ATE448222T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
PCT/US2004/032921 WO2005032488A2 (en) 2003-10-03 2004-09-29 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Publications (1)

Publication Number Publication Date
ATE448222T1 true ATE448222T1 (de) 2009-11-15

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04789522T ATE448222T1 (de) 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Country Status (15)

Country Link
US (1) US7109332B2 (de)
EP (1) EP1668002B1 (de)
JP (1) JP2007507551A (de)
KR (1) KR20060113700A (de)
CN (1) CN1863798B (de)
AT (1) ATE448222T1 (de)
AU (1) AU2004278030C1 (de)
CA (1) CA2540214A1 (de)
DE (1) DE602004024093D1 (de)
ES (1) ES2334795T3 (de)
IL (1) IL174446A (de)
MX (1) MXPA06003618A (de)
PL (1) PL1668002T3 (de)
PT (1) PT1668002E (de)
WO (1) WO2005032488A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1700850B1 (de) * 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalaninderivat
AU2005292314B2 (en) * 2004-09-29 2011-11-03 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
AR056762A1 (es) * 2005-11-03 2007-10-24 Portola Pharm Inc (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
EP2129665A1 (de) 2007-04-05 2009-12-09 CV Therapeutics Inc. Chinazolinonderivate als aldh-2-inhibitoren
US20100113391A1 (en) 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
ES2536090T3 (es) 2009-01-19 2015-05-20 Abbvie Inc. Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias
CN104945311A (zh) * 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
AU2016222278B2 (en) 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック, インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CA3071150A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
EP3759098A1 (de) 2018-02-26 2021-01-06 Genentech, Inc. Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen
EP3759077A1 (de) 2018-03-02 2021-01-06 Inflazome Limited Neuartige verbindungen
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020116662A1 (ja) 2018-12-06 2020-06-11 第一三共株式会社 シクロアルカン−1,3−ジアミン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板adp受容体阻害剤
DE60114994T2 (de) 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
ES2334795T3 (es) 2010-03-16
PL1668002T3 (pl) 2010-02-26
HK1093973A1 (en) 2007-03-16
US20050107357A1 (en) 2005-05-19
AU2004278030A1 (en) 2005-04-14
EP1668002A2 (de) 2006-06-14
CN1863798B (zh) 2011-08-31
JP2007507551A (ja) 2007-03-29
EP1668002A4 (de) 2006-12-20
MXPA06003618A (es) 2006-08-11
US7109332B2 (en) 2006-09-19
IL174446A (en) 2012-02-29
WO2005032488A3 (en) 2005-05-12
IL174446A0 (en) 2006-08-01
PT1668002E (pt) 2009-11-25
CN1863798A (zh) 2006-11-15
WO2005032488A2 (en) 2005-04-14
AU2004278030C1 (en) 2010-12-02
EP1668002B1 (de) 2009-11-11
CA2540214A1 (en) 2005-04-14
DE602004024093D1 (de) 2009-12-24
AU2004278030B2 (en) 2010-07-01
KR20060113700A (ko) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE448222T1 (de) 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MXPA04004457A (es) Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina.
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
GR3034398T3 (en) 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides and their use as pest-control agents
ATE366724T1 (de) Kondensierte heterocyclische derivate
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
WO2004004730A3 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
EA200401470A1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
MY146599A (en) New azetidine compounds
AU2003249484A1 (en) Novel bio-active molecules
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
PL1628968T3 (pl) Związki 4-imidazolino-2-onu
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
BR0307424A (pt) Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários
EA200401099A1 (ru) Производные гетероциклического амида
ES2193047T3 (es) (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.
EA200200352A1 (ru) Фенил- и пиридил-тетрагидропиридины, обладающие ингибирующей активностью в отношении фактора некроза опухоли (фно)
AU4932590A (en) Cyclic guanidines uses as calcium antagonists
TW326385B (en) Iminooxybenzyl compounds, their preparation and their use
GB0224306D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
SE0301744D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668002

Country of ref document: EP